



Special issue: Topics from The 45 the Annual Scientific meeting of the Japanese Society of Hypertension (JSH 2024)

Our mission in the Japanese Society of Hypertension (JSH) Future Plan: a baton-connection from JSH Osaka 2023 to Fukuoka 2024

Koichi Node^{1,2} · Atsushi Tanaka^{1,3}

Keywords The Japanese Society of Hypertension · Future Plan · NEO-HYPERTENSION

Received: 15 February 2024 / Accepted: 24 February 2024 / Published online: 14 March 2024
© The Author(s), under exclusive licence to The Japanese Society of Hypertension 2024

Hypertension is one of the biggest contributors to non-communicable diseases and a major burden on public health worldwide; therefore, a system-wide transformation in hypertension research and clinical care is urgently required [1]. However, this goal is difficult to accomplish in the medical field alone. In this context, a multi-axis, multi-faceted, and continued approach through cross-sectional collaboration among industry, government, and academia is necessary, which will build the future of hypertension science and contribute advancements to society.

In 2018, the Japanese Society of Hypertension (JSH) established the JSH Future Plan with the slogan “Good Blood Pressure for Lively 100 Years”, with the goal of decreasing the number of hypertensive individuals by seven million over the next decade and correspondingly extend healthy life expectancy [2]. We are now working on three pillars of the task force: (A) Establishment of a lifelong hypertension care system, (B) Development of new academic fields in hypertension science, and (C) Social edification and building a social model for self-controlled blood pressure (BP) and

zero-hypertension. These pillars overlap each other and are expected to be implemented in society at large and build our ideal of “NEO-HYPERTENSION harmonized with society” (Fig. 1). Many colleagues in various parts of Japan are currently working hard toward our mission.

Regarding the exploration of new academic fields in hypertension science, following global motivation toward BP management/control in children and adolescents [3], the JSH also focuses on this issue. To this end, it is essential to educate students about their own BP and hypertension and to encourage further academic and public efforts [4]. Moreover, the JSH first proposed the academic concept of “onco-hypertension” to elucidate the unproven cross-talk between cancer and hypertension and provide total-care for patients fighting against cancer [5]. Additionally, other special

These authors contributed equally: Koichi Node, Atsushi Tanaka

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41440-024-01644-4>.


✉ Koichi Node
node@cc.saga-u.ac.jp

✉ Atsushi Tanaka
tanaka2@cc.saga-u.ac.jp

¹ Department of Cardiovascular Medicine, Saga University, Saga, Japan

² President of the 46th annual scientific meeting of the JSH 2024 in Fukuoka, Fukuoka, Japan

³ Chief of the secretariat of the 46th annual scientific meeting of the JSH 2024 in Fukuoka, Fukuoka, Japan



"Good Blood Pressure for Lively 100 Years"

Fig. 1 Our mission in the JSH Future Plan. JSH is now working in collaboration with industry, government, and academia to build the JSH Future Plan. Through these actions, we seek to build “NEO-HYPERTENSION harmonized with society,” which is the catchphrase of the 46th annual scientific meeting of the JSH 2024 in Fukuoka, and to finally achieve “Good Blood Pressure for Lively 100 Years”, the slogan of the JSH Future Plan. JSH Japanese Society of Hypertension

committees and working groups for JSH tasks, such as renal denervation, basic research, practical medicine, digital hypertension, and diversity, are also progressing and have shown their achievements at the 45th annual scientific meeting of JSH 2023 held in Osaka (President Prof. Rakugi, Osaka University) [6]. Some of these findings were simultaneously published in *Hypertension Research*, the official journal of the JSH, as fast-track papers, thus heightening their impact and creating synergistic effects with *Hypertension Research* [7]. These advances will further strengthen the academic aspect, which is the cornerstone of JSH, and provide new evidence for future guidelines for the management of hypertension planned for 2025.

In the 46th annual scientific meeting of the JSH 2024 in Fukuoka, we are planning the first special symposium on the project of creating a “zero-hypertension city.” Seventeen municipalities across Japan had participated in this project, and their unique approaches will be presented. We hope that this project will lead to a community-based self-care system for hypertension in our society.

Finally, we now face various changes and innovations in the field of hypertension; therefore, we are preparing a scientific program for JSH 2024 so that attendees can meet and feel the latest hypertension science. See your colleagues in early autumn in Fukuoka (Supplementary Fig. S1).

Acknowledgements We would like to express our deepest gratitude to everyone who is committed to all aspects of JSH activities.

Compliance with ethical standards

Conflict of interest KN has received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly

Japan, Kowa, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Otsuka, Tsumura & Co; research grant from Astellas, Bayer Yakuhin, Boehringer Ingelheim Japan, Fujiyaku, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Novartis Pharma; scholarship from Abbott, Boehringer Ingelheim Japan, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Teijin Pharma. AT has received honoraria from Boehringer Ingelheim Japan and Mochida; research funding from GlaxoSmithKline, Takeda, Bristol Myers Squibb, and Novo Nordisk.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Dzau VJ, Balatbat CA. Future of Hypertension. *Hypertension*. 2019;74:450–7.
2. Node K, Kishi T, Tanaka A, Itoh H, Rakugi H, Ohya Y, et al. The Japanese Society of Hypertension-Digest of plan for the future. *Hypertens Res*. 2018;41:989–90.
3. Falkner B, Gidding SS, Baker-Smith CM, Brady TM, Flynn JT, Malle LM, et al. Pediatric primary hypertension: an under-recognized condition: a scientific statement from the American Heart Association. *Hypertension*. 2023;80:e101–11.
4. Tanaka A, Yajima A, Kitaoka K, Natsuaki M, Yoshioka G, Kaneko H, et al. Blood pressure in Japanese junior and senior high school students. *Hypertens Res*. 2024;47:195–6.
5. Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, et al. New concept of onco-hypertension and future perspectives. *Hypertension*. 2021;77:16–27.
6. Rakugi H. Healthy 100-year life in hypertensive patients: messages from the 45th Annual Meeting of the Japanese Society of Hypertension. *Hypertens Res*. 2024;47:1–3.
7. Mogi M, Tanaka A, Node K, Tomitani N, Hoshida S, Narita K, et al. 2023 update and perspectives. *Hypertens Res*. 2024;47:6–32.